摘要:
Methods of using substituted 3,5-dithio-, disulfinyl-or disulfonyl-isothiazole derivatives to treat cancer or inflammation in a mammal and pharmaceutical compositions containing such derivatives are disclosed.
摘要:
This invention is directed to methods of using compounds having the structure: and including stereoisomers, solvates, and pharmaceutically acceptable salts thereof, wherein each of R1, R2, R3 and R4 is independently selected from hydrogen, R5, R6, and R7; R5 is selected from alkyl, heteroalkyl, aryl and heteroaryl; R6 is selected from (R5)n-alkylene, (R5)n-heteroalkylene, (R5)n-arylene and (R5)n-heteroarylene; R7 is selected from (R6)n-alkylene, (R6)n-heteroalkylene, (R6)n-arylene, and (R6)n-heteroarylene; and n is selected from 0, 1, 2, 3, 4 and 5, where R1 and R2 may together form a heterocyclic structure including the nitrogen to which they are both attached, and R3 and R4 may together form a heterocyclic structure including the nitrogen to which they are both attached; and each of L1 and L2 is independently selected from -A1-A2-A3- where each of A1, A2, and A3 is independently selected from a direct bond, alkylene, heteroalkylene, arylene and heteroarylene. These compounds are useful in treating hyperproliferative disorders and inducing apoptosis.
摘要:
Methods of using thiazolidinedithione derivatives to treat cancer, neurodegenerative disease, diabetes, renal disease or inflammation in a mammal and pharmaceutical compositions containing such derivatives are disclosed.
摘要:
Methods of using benzothiophenone derivatives to treat cancer or inflammation in a mammal and pharmaceutical compositions containing such derivatives are disclosed.
摘要:
Pharmaceutical pyrazolybenzothiazole compositions of formula (1) are provided. The compositions may be pharmaceutically acceptable salts. R1, R2 and R3 at each occurrence are independently selected from amino, aminosulfinyl, aminosulfonyl, aryl, azido, halogen, heteroalkyl, heteroaryl, hydrazinyl, hydrocarbyl, hydrogen, hydroxyl, nitro, nitroso, phosphate, phosphinate, phosphonate, phosphonium, phosphorothioate, phosphoryl, sulfamoyl, sulfate, sulfinic acid, sulfonamido, sulfonate, sulfonic acid, sulfonyl, sulfoxido, thiol, thioureido, and ureido, and R4 is selected from hydrogen, heteroalkyl, heteroaryl, and hydrocarbyl.
摘要翻译:提供式(1)的药物吡唑并苯并噻唑组合物。 组合物可以是药学上可接受的盐。 R 1,R 2,R 3和R 3各自独立地选自氨基,氨基亚磺酰基,氨基磺酰基,芳基,叠氮基,卤素,杂烷基, 杂芳基,肼基,烃基,氢,羟基,硝基,亚硝基,磷酸酯,次膦酸酯,膦酸酯,鏻,硫代磷酸酯,磷酰基,氨磺酰,硫酸根,亚磺酸,亚磺酰氨基,磺酸,磺酸,磺酰基,亚砜基,硫醇,硫脲基和脲基 R 4选自氢,杂烷基,杂芳基和烃基。
摘要:
Methods of using thiazolidine derivatives of formula (I) to treat cancer, inflammation, or other disorders related to the activities of protein phosphatases PTPN12 or PTPN2 in a mammal are disclosed. Pharmaceutical compositions containing such derivatives are disclosed.
摘要:
The present invention provides mice that have had their PTP-1B genes disrupted by targeted homologous recombination. The mice have no detectable PTP-1B protein, yet appear to be physiologically normal. However, in the fed state on a normal diet, the mice have half the level of circulating insulin as their wild-type littermates. In glucose and insulin tolerance tests, the mice show an increased insulin sensitivity. When fed a high fat, high carbohydrate diet, the mice show a resistance to weight gain as compared to their wild-type littermates. Methods of making the mice and cell lines derived from the mice are also provided. The present invention also provides methods of identifying inhibitors of the enzymatic activity of PTP-1B as well as inhibitors identified by such methods.